Pulmonary Mycobacterium bovis BCG Vaccination Confers Dose-Dependent Superior Protection Compared to That of Subcutaneous Vaccination-Reference-Cited by-同舟云学术

Pulmonary Mycobacterium bovis BCG Vaccination Confers Dose-Dependent Superior Protection Compared to That of Subcutaneous Vaccination

Published:2014-04 Issue:4 Volume:21 Page:594-597
ISSN:1556-6811
Container-title:Clinical and Vaccine Immunology
language:en
Short-container-title:Clin Vaccine Immunol

Author:

Aguilo Nacho¹²,Toledo Ana Maria³,Lopez-Roman Eva Maria³,Perez-Herran Esther³,Gormley Eamonn⁴,Rullas-Trincado Joaquin³,Angulo-Barturen Iñigo³,Martin Carlos¹²⁵

Affiliation:

1. Grupo de Genética de Micobacterias, Departmento de Microbiología, Medicina Preventiva y Salud Pública, Faculty of Medicine, Universidad de Zaragoza, Zaragoza, Spain

2. CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain

3. Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain

4. School of Veterinary Medicine, University College Dublin (UCD), Dublin, Ireland

5. Servicio de Microbiología, Hospital Universitario Miguel Servet, IIS Aragón, Zaragoza, Spain

Abstract

ABSTRACT Worldwide, the Mycobacterium bovis BCG vaccine is one of the most widely used vaccines. However, it appears to be ineffective in preventing pulmonary tuberculosis. Here, we show that pulmonary BCG vaccination of mice with a broad dose range provides superior protection against Mycobacterium tuberculosis challenge compared to that of subcutaneous vaccination.

Publisher

American Society for Microbiology

Subject

Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy

Link

https://journals.asm.org/doi/pdf/10.1128/CVI.00700-13

Reference19 articles.

1. The success and failure of BCG — implications for a novel tuberculosis vaccine

2. Recent developments in tuberculosis vaccines

3. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

4. Should a new tuberculosis vaccine be administered intranasally?

5. Aerogenic BCG Vaccination Against Tuberculosis in Animal and Human Subjects

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BCG infection dose guides dendritic cell migration and T cell priming in the draining lymph node;Scandinavian Journal of Immunology;2023-11-21

2. Intravenous BCG Vaccination of Diversity Outbred Mice Results in Moderately Enhanced Protection against Challenge with Mycobacterium tuberculosis Compared to Intradermal Vaccination;Infection and Immunity;2023-07-18

3. Advance in strategies to build efficient vaccines against tuberculosis;Frontiers in Veterinary Science;2022-11-24

4. A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19;Frontiers in Immunology;2022-08-26

5. Intravenous BCG driven antigen recognition in a murine tuberculosis model;Comparative Immunology, Microbiology and Infectious Diseases;2022-08